Comparison · NCT00617669-sae
ZD4054 + Docetaxel vs Placebo + Docetaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZD4054 + Docetaxel vs Placebo + Docetaxel: serious adverse events. Trial comparisons, record NCT00617669-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00617669-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.41 | 0.369 | 0.453 | wilson | |
| Risk in group 2 | 0.387 | 0.346 | 0.429 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0233 | -0.0359 | 0.0823 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.913 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.86 | 1.41 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ZD4054 + Docetaxel than on Placebo + Docetaxel | 42.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZD4054 + Docetaxel | XD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks | 214 | 522 | EG000 |
| Group 2 | Placebo + Docetaxel | placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks | 203 | 525 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
- NCT number
- NCT00617669
- Phases
- PHASE3
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, ZD4054, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2012-05-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00617669?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00617669-sae